IRADIMED CORPORATION
US ˙ NasdaqGM ˙ US46266A1097

SecurityIRMD / IRADIMED CORPORATION
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership83,449 shares
Latest Disclosed Value $ 8,032,801
Qube Research & Technologies Ltd reports 36.90% increase in ownership of IRMD / IRADIMED CORPORATION

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 83,449 shares of IRADIMED CORPORATION (US:IRMD) valued at $8,032,801 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 60,958 shares of IRADIMED CORPORATION. This represents a change in shares of 36.90% during the quarter. The current value of the position is $7,603,873 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F IRADIMED COM 46266A109 83,449 22,491 36.90 8,033 35.47 0.0089
2026-02-17 2025-12-31 13F IRADIMED COM 46266A109 60,958 4,132 7.27 5,930 46.65 0.0060
2025-11-14 2025-09-30 13F IRADIMED COM 46266A109 56,826 8,289 17.08 4,044 39.32 0.0042
2025-08-14 2025-06-30 13F IRADIMED COM 46266A109 48,537 964 2.03 2,902 16.27 0.0029
2025-05-15 2025-03-31 13F IRADIMED COM 46266A109 47,573 1,182 2.55 2,497 -2.16 0.0029
2025-02-14 2024-12-31 13F IRADIMED COM 46266A109 46,391 12,232 35.81 2,552 48.57 0.0033
2024-11-14 2024-09-30 13F IRADIMED COM 46266A109 34,159 11,162 48.54 1,718 70.00 0.0025
2024-08-14 2024-06-30 13F IRADIMED COM 46266A109 22,997 6,086 35.99 1,010 35.94 0.0016
2024-05-14 2024-03-31 13F IRADIMED COM 46266A109 16,911 11,426 208.31 744 185.77 0.0012
2024-02-13 2023-12-31 13F IRADIMED COM 46266A109 5,485 2,720 98.37 260 113.11 0.0005
2023-11-13 2023-09-30 13F IRADIMED COM 46266A109 2,765 2,765 123 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.